Skip to main content
. Author manuscript; available in PMC: 2022 Mar 1.
Published in final edited form as: Amyloid. 2020 Aug 19;28(1):30–34. doi: 10.1080/13506129.2020.1810010

Figure 1:

Figure 1:

Time to event analysis of primary outcome including stroke, TIA, major bleed, or death in Patients with ATTR-CA and AF treated with warfarin compared with ATTR-CA and AF treated with NOACs. This Kaplan-Meier curve demonstrates the freedom from primary outcome comparing patients treated with warfarin with patients treated with NOACs (p=0.35).